<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854500</url>
  </required_header>
  <id_info>
    <org_study_id>2018-003090-95</org_study_id>
    <nct_id>NCT03854500</nct_id>
  </id_info>
  <brief_title>The Norwegian Tenecteplase Stroke Trial 2</brief_title>
  <acronym>NOR-TEST 2</acronym>
  <official_title>A Randomised Trial of Tenecteplase vs. Alteplase in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Alteplase is the only approved acute drug treatment in ischemic stroke and aims&#xD;
      at dissolving arterial clots causing cerebral ischemia. The overall benefit of alteplase is&#xD;
      substantial. However, there is considerable room for improvement as 2/3 of patients with&#xD;
      large clots may not achieve reopening of the vessel and up to 40% of the patients remain&#xD;
      severely disabled or die.&#xD;
&#xD;
      Tenecteplase, a modified tissue plasminogen activator, has been shown to be a more efficient&#xD;
      and safer thrombolytic drug than alteplase in pre-clinical studies. Tenecteplase has replaced&#xD;
      alteplase as thrombolytic treatment in myocardial infarction and may also be the drug of&#xD;
      choice in ischemic stroke.&#xD;
&#xD;
      Tenecteplase and alteplase had a similar safety profile in the NOR-TEST trial and there were&#xD;
      no differences in efficacy between the two treatment groups. However, a majority of patients&#xD;
      had mild stroke which may be associated with a natural favorable prognosis.&#xD;
&#xD;
      In spite of these neutral results, tenecteplase has the potential to replace alteplase as the&#xD;
      drug of choice, based on a better pharmacological profile and a simpler practical&#xD;
      administration. There is, however, need for a higher number of patients to prove the efficacy&#xD;
      and safety of tenecteplase.&#xD;
&#xD;
      Hypothesis: Tenecteplase 0.4 mg/kg is non-inferior compared with alteplase 0.9 mg/kg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: To compare efficacy and safety of tenecteplase 0.4 mg/kg (single bolus) vs.&#xD;
      alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes) a) within 4½ hours after symptom&#xD;
      onset; b) within 4½ hours after awakening with stroke symptoms, and c) as bridging therapy&#xD;
      within 4½ hours before thrombectomy.&#xD;
&#xD;
      Study design: NOR-TEST-2 is a multi-centre PROBE (prospective randomised, open-label, blinded&#xD;
      endpoint) trial, designed to establish non-inferiority of tenecteplase as compared with&#xD;
      alteplase for consecutively admitted patients with acute ischaemic stroke treated within 4½&#xD;
      hours after symptom onset. Randomisation tenecteplase:alteplase is 1:1.&#xD;
&#xD;
      Endpoints: Primary endpoint is functional outcome (mRS 0-1) at 90 days (efficacy). Secondary&#xD;
      endpoints include rates of cerebral hemorrhages on CT/MR at 24-48 hours and mortality&#xD;
      (safety).&#xD;
&#xD;
      Patient recruitment: All patients admitted to hospital with acute ischaemic stroke eligible&#xD;
      for standard iv thrombolysis with alteplase and with pre-stroke mRS&lt;3 and NIHSS score of &gt;5&#xD;
      on admission are potentially eligible for NOR-TEST-2. Based on power calculations from&#xD;
      NOR-TEST, NOR-TEST 2 aims at including 1036 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with favorable functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale 0-1 (favorable= 0-1, unfavorable 2-6)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic cerebral hemorrhage</measure>
    <time_frame>24-48 hours</time_frame>
    <description>Proportion of patients with haemorrhagic infarct/haematoma as defined by CT or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any cerebral haemorrhage</measure>
    <time_frame>24-48 hours</time_frame>
    <description>Proportion of patients haemorrhagic infarct/haematoma as defined by CT or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major neurological improvement</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of patients &gt;3 Points improvement by NIHSS score or NIHSS score 0 (NIHSS score range is 0-42)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional handicap</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal shift analysis of modified Rankin scale (0-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients who died</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenecteplase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>0.4 mg/kg single bolus intravenously</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General inclusion criteria&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Ischaemic stroke with clinical symptoms corresponding to National Institutes of Health&#xD;
             Stroke Scale Score (NIHSS) of &gt;5. All stroke sub-types and vascular distributions are&#xD;
             eligible. A visible arterial occlusion is not required for inclusion.&#xD;
&#xD;
          -  Treatment &lt;4½ hours after stroke onset or after awakening with symptoms.&#xD;
&#xD;
          -  Informed consent by patient or by patient's family&#xD;
&#xD;
        Specific sub-set inclusion criteria&#xD;
&#xD;
          -  Wake-Up Stroke: FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist or&#xD;
             neurologist.&#xD;
&#xD;
          -  Thrombectomy: Occlusion of intracerebral artery technically accessible for&#xD;
             endovascular embolectomy as defined by local treatment protocols.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Prestroke modified rankin scale of ≥3&#xD;
&#xD;
          -  Large areas of hypodense ischaemic changes on baseline CT;&#xD;
&#xD;
          -  Patients with systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;110 mm&#xD;
             Hg in spite of acute antihypertensive treatment;&#xD;
&#xD;
          -  Pregnant women (are treated with alteplase);&#xD;
&#xD;
          -  Women with possible pregnancy (are treated with alteplase)&#xD;
&#xD;
          -  Beast feeding women, if a 24 hours stop of feeding is not feasible.&#xD;
&#xD;
          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is&#xD;
             normal;&#xD;
&#xD;
          -  Known bleeding diathesis; use of oral anticoagulants with no antidot, INR ≥1,4;&#xD;
             heparin &lt;48 hours and increased APTT; low molecular weight heparin(oid) &lt;24 hours;&#xD;
             another investigational drug &lt;14 days;&#xD;
&#xD;
          -  Patients with arterial puncture at a noncompressible site or lumbar puncture &lt;7 days;&#xD;
             major surgery or serious trauma &lt;14 days; gastrointestinal or urinary tract hemorrhage&#xD;
             &lt;14 days; clinical stroke &lt;2 months; history of intracranial haemorrhage; CNS&#xD;
             neurosurgery &lt;2 months; serious head trauma &lt;2 months; pericarditis; sepsis; any&#xD;
             serious medical illness likely to interact with treatment; confounding pre-existent&#xD;
             neurological or psychiatric disease; unlikely to complete follow-up;&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, puts a patient at risk if&#xD;
             treated with thrombolysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, Tobro H, Kaur K, Stankiewicz M, Carlsson M, Morsund Å, Idicula T, Aamodt AH, Lund C, Næss H, Waje-Andreassen U, Thomassen L. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2.</citation>
    <PMID>28780236</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tenecteplase</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Alteplase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

